BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 27256431)

  • 21. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Nell S; Borel Rinkes IHM; Verkooijen HM; Bonsing BA; van Eijck CH; van Goor H; de Kleine RHJ; Kazemier G; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; Vriens MR;
    Ann Surg; 2018 Feb; 267(2):352-356. PubMed ID: 27811505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
    van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
    Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
    Marini F; Giusti F; Tonelli F; Brandi ML
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study.
    Tamagno G; Scherer V; Caimo A; Bergmann SR; Kann PH
    Digestion; 2018; 98(2):112-118. PubMed ID: 29698969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors.
    Sagami R; Nishikiori H; Ikuyama S; Murakami K
    World J Gastroenterol; 2017 Oct; 23(37):6911-6919. PubMed ID: 29085235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of biomarker tests for diagnosis of neuroendocrine tumours.
    Hofland J; Zandee WT; de Herder WW
    Nat Rev Endocrinol; 2018 Nov; 14(11):656-669. PubMed ID: 30158549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of plasma chromogranin A in neuroendocrine tumours.
    Tomassetti P; Migliori M; Simoni P; Casadei R; De Iasio R; Corinaldesi R; Gullo L
    Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):55-8. PubMed ID: 11204811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs.
    van Vliembergen ENM; Eijkelenkamp H; Valk GD; Vriens MR; Meijer GJ; Intven MPW; de Laat JM
    Front Endocrinol (Lausanne); 2023; 14():994370. PubMed ID: 37305036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.
    Thomas-Marques L; Murat A; Delemer B; Penfornis A; Cardot-Bauters C; Baudin E; Niccoli-Sire P; Levoir D; Choplin Hdu B; Chabre O; Jovenin N; Cadiot G;
    Am J Gastroenterol; 2006 Feb; 101(2):266-73. PubMed ID: 16454829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing?
    Ramamoorthy B; Nilubol N
    Surg Oncol Clin N Am; 2023 Apr; 32(2):315-325. PubMed ID: 36925188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.
    Pavel ME; Chen D; He W; Cushman S; Voi M; de Vries EGE; Baudin E; Yao JC
    Pancreas; 2017 Jul; 46(6):751-757. PubMed ID: 28609362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.
    Nehar D; Lombard-Bohas C; Olivieri S; Claustrat B; Chayvialle JA; Penes MC; Sassolas G; Borson-Chazot F
    Clin Endocrinol (Oxf); 2004 May; 60(5):644-52. PubMed ID: 15104570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1.
    Lewis MA; Thompson GB; Young WF
    World J Surg; 2012 Jun; 36(6):1375-81. PubMed ID: 22382771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of p27
    Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
    J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.